WallStreetZenWallStreetZen

NASDAQ: NGNE
Neurogene Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NGNE

Based on 1 analyst offering 12 month price targets for Neurogene Inc

Min Forecast
$70.00+240.63%
Avg Forecast
$70.00+240.63%
Max Forecast
$70.00+240.63%

Should I buy or sell NGNE stock?

Based on 1 analyst offering ratings for Neurogene Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NGNE's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NGNE as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their NGNE stock forecasts and price targets.

NGNE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-11-13

1 of 1

Forecast return on equity

Is NGNE forecast to generate an efficient return?

Company
N/A
Industry
250.21%
Market
226.77%

Forecast return on assets

Is NGNE forecast to generate an efficient return on assets?

Company
N/A
Industry
89.93%

NGNE earnings per share forecast

What is NGNE's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$4.28
Avg 2 year Forecast
-$5.31
Avg 3 year Forecast
-$6.12

NGNE revenue forecast

What is NGNE's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$0.0

NGNE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NGNE$20.55$70.00+240.63%Buy
MREO$2.00$6.33+216.65%Strong Buy
RLMD$4.35$10.00+129.89%Buy
ALLO$1.42$7.00+392.96%Buy
CLLS$4.37$8.00+83.07%Strong Buy
View Top Biotech Stocks

Neurogene Stock Forecast FAQ

Is Neurogene Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: NGNE) stock is to Buy NGNE stock.

Out of 1 analyst, 0 (0%) are recommending NGNE as a Strong Buy, 1 (100%) are recommending NGNE as a Buy, 0 (0%) are recommending NGNE as a Hold, 0 (0%) are recommending NGNE as a Sell, and 0 (0%) are recommending NGNE as a Strong Sell.

If you're new to stock investing, here's how to buy Neurogene stock.

What is NGNE's earnings growth forecast for 2025-2027?

(NASDAQ: NGNE) Neurogene's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 43.55%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.4%.

Neurogene's earnings in 2025 is -$85,130,000.On average, 8 Wall Street analysts forecast NGNE's earnings for 2025 to be -$66,294,795, with the lowest NGNE earnings forecast at -$64,818,617, and the highest NGNE earnings forecast at -$67,008,875. On average, 8 Wall Street analysts forecast NGNE's earnings for 2026 to be -$82,284,916, with the lowest NGNE earnings forecast at -$98,518,226, and the highest NGNE earnings forecast at -$70,587,019.

In 2027, NGNE is forecast to generate -$94,744,911 in earnings, with the lowest earnings forecast at -$104,438,428 and the highest earnings forecast at -$90,266,810.

What is NGNE's revenue growth forecast for 2025-2027?

(NASDAQ: NGNE) Neurogene's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 99.5%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.47%.

Neurogene's revenue in 2025 is $0.On average, 8 Wall Street analysts forecast NGNE's revenue for 2025 to be $0, with the lowest NGNE revenue forecast at $0, and the highest NGNE revenue forecast at $0. On average, 8 Wall Street analysts forecast NGNE's revenue for 2026 to be $0, with the lowest NGNE revenue forecast at $0, and the highest NGNE revenue forecast at $0.

In 2027, NGNE is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is NGNE's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: NGNE) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 89.93%.

What is NGNE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year NGNE price target, the average NGNE price target is $70.00, with the highest NGNE stock price forecast at $70.00 and the lowest NGNE stock price forecast at $70.00.

The Wall Street analyst predicted that Neurogene's share price could reach $70.00 by Nov 13, 2026. The average Neurogene stock price prediction forecasts a potential upside of 240.63% from the current NGNE share price of $20.55.

What is NGNE's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: NGNE) Neurogene's current Earnings Per Share (EPS) is -$4.11. On average, analysts forecast that NGNE's EPS will be -$4.28 for 2025, with the lowest EPS forecast at -$4.18, and the highest EPS forecast at -$4.33. On average, analysts forecast that NGNE's EPS will be -$5.31 for 2026, with the lowest EPS forecast at -$6.36, and the highest EPS forecast at -$4.56. In 2027, NGNE's EPS is forecast to hit -$6.12 (min: -$6.74, max: -$5.83).

What is NGNE's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: NGNE) forecast ROE is N/A, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.